Abstract
Objective: This study aimed to compare short-term quality of life (QOL) outcomes and perioperative parameters between transurethral resection of the prostate (TURP) and thulium laser vaporization of the prostate (ThuVap) in patients with benign prostatic hyperplasia (BPH). Materials and Methods: A retrospective analysis was conducted on 106 patients with BPH who underwent either TURP (n = 58) or ThuVap (n = 48) at our institution between April 2021 and August 2024. Preoperative and postoperative evaluations included the International Prostate Symptom Score (I-PSS), Overactive Bladder Symptom Score (OABSS), QOL index, and uroflowmetry. Perioperative outcomes, including operative time, catheterization duration, and hemoglobin (Hb) reduction, were also analyzed. Results: Both TURP and ThuVap showed sustained improvements in I-PSS, OABSS, and QOL index during the 3-month follow-up period, with no significant differences between the groups. ThuVap demonstrated a significantly lower rate of Hb reduction on the first postoperative day compared to TURP (5.9% vs. 8.5%, P < 0.05), likely due to reduced intraoperative bleeding. Although ThuVap had a shorter mean operative time (82.3 vs. 99.3 minutes), this difference was not statistically significant (P = 0.1). Discussion: The findings indicate that both TURP and ThuVap effectively improve postoperative QOL. ThuVap's reduced bleeding may provide advantages in patients with higher cardiovascular or bleeding risks. However, variations in operative time between studies may be influenced by factors such as surgeons' experience and institutional protocols. Conclusion: Both TURP and ThuVap are effective surgical options for improving QOL in BPH patients. However, surgical efficiency and outcomes may be influenced by the surgeon's expertise and the preoperative condition of the patients. ThuVap offers additional benefits of reduced intraoperative bleeding, which may support its use in selected cases.

This publication has 18 references indexed in Scilit: